aspiringchemist
Bluelighter
- Joined
- Nov 17, 2015
- Messages
- 453
Late to the party but I think it’s ridiculous that they’re marketing this as some new fast acting antidepressant. I know it’s been said already, but jesus man they just combined two old and well known drugs. It’s sad when you really understand just how strong the use of marketing is in pharmaceuticals sales. With esketamine’s approval what is the point? I’ve yet to see any large percentage of people actually be prescribed ket as a take home daily ofc.
I would however like to try this newly approved medicine for those with disruptive sleep apnea. I can’t recall the name but it’s C-IV in the US. Some sort of NDRI I assume but I’ll go check
Update Solriamfetol, a dopamine/norepinephrine reuptake inhibitor (DNRI) (brand name SUNOSI)
I would however like to try this newly approved medicine for those with disruptive sleep apnea. I can’t recall the name but it’s C-IV in the US. Some sort of NDRI I assume but I’ll go check
Update Solriamfetol, a dopamine/norepinephrine reuptake inhibitor (DNRI) (brand name SUNOSI)